Plasma pTau217 Cutoffs for Clinical Use - Top-Institutions - MDSpire

Plasma pTau217 Cutoffs for Clinical Use

Researchers assess how biological factors influence plasma biomarker interpretation for amyloid detection.

  • By

  • Kathryn Wighton

  • February 4, 2026

  • 4 min

Share

Top Institutions in Internal Medicine

Brief introduction explaining scope and methodology.

  • #1

    University of Gothenburg
    University of Gothenburg

    Gothenburg, Sweden

    Key Differentiators

    • Neurology
    • Neurodegenerative Disease
    • Biomarker Research

  • #2

    Roche Diagnostics
    Roche Diagnostics

    Basel, Switzerland

    Key Differentiators

    • Clinical Diagnostics
    • Biomarker Assay Development
    • Neurology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neurology
    • Neuroimaging
    • Alzheimer’s Disease Research

  • #4

    Korean Dementia Association / Korea Brain Research Institute
    Korean Dementia Association / Korea Brain Research Institute

    Daegu, South Korea

    Key Differentiators

    • Neurology
    • Dementia Research
    • Population Cohort Studies

Original Source(s)

Plasma pTau217 Cutoffs for Clinical Use

  • by Kathryn Wighton

  • February 4, 2026

Related Content

Not All Poststroke Cognitive Patterns Plateau

Researchers identify divergent recovery, persistence, and decline patterns across cognitive domains following stroke.

Human-AI Interaction in Kidney Transplant Decision Support Systems: Qualitative Study of Patient and Support Person Expectations

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.